Oslo Balloon Angioplasty Versus Conservative Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00222196|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : July 6, 2011
Background: Percutaneous transluminal angioplasty (PTA) has been popularized as a simple, effective and cheap treatment achieving 50-70% symptomatic patency rates in patients with peripheral occlusive disease.. However, the fact remains that the indication for performing PTA are still more based on opinions than on scientific data.
The purpose of the trial was to randomize patients primarily referred for intermittent claudication into two groups: One group was offered conservative treatment; the other group was offered conservative treatment combined with PTA.
Primary outcome: The patient quality of life. Secondary outcome:Pain-free walking distance; pain-score; death; amputation; changes in relevant biomarkers
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Vascular Disease||Procedure: lifestyle, PTA||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Oslo Balloon Angioplasty Versus Conservative Treatment|
|Study Start Date :||November 2000|
|Study Completion Date :||December 2004|
- The patient quality of life.
- Pain-free walking distance; pain-score; death; amputation; changes in relevant biomarkers
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00222196
|Principal Investigator:||Marthe Nylaende, MD||Aker and Ullevål University Hospitals, Oslo, Norway|